Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

Bayer symbol

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

A first for Loxo, and a second mutation-based targeted drug

- PMLiVE

NHS says Humira biosimilar deal will save £300m

AbbVie also submitted a bid into tender process

- PMLiVE

Zafgen shares tumble after FDA places hold on diabetes trial

Regulator concerns based on deaths with previous drug

- PMLiVE

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Partners tap into expanding market - but have multinationals to compete with

- PMLiVE

Novartis gets EU nod for Luxturna gene therapy

Approval comes almost a year after it was secured a green light in the US

- PMLiVE

EU27 backs Brexit terms – now the hard part starts for May

House of Commons looks set to oppose the deal

Medical Advisor: A new role is created at Porterhouse Medical

Porterhouse Medical Group is delighted to announce that Dr. Beth Wynne-Evans will be taking on the role of Medical Advisor.This is a new role within Porterhouse, created to maximise the...

Porterhouse Medical Group

Comment: the new UK pricing deal – welcome news, but lessons to be learned

Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement

- PMLiVE

PMEA 2018: celebrating excellence in improving patient outcomes

Among the winners were AbbVie, Lucid Group and Takeda

- PMLiVE

New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

Decades old PPRS name to go

- PMLiVE

Astellas makes another gene therapy play with Juventas deal

Targeting faecal incontinence, which affects 50m worldwide

Another spellbinding result for Lucid Group at the 2018 PMEAs

Lucid’s pioneering approach to medical education was clear to see as they scooped two top awards and a high commendation at last night’s awards ceremony.The first award was gained in...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links